Orthofix Medical Inc. Announces Preliminary 2023 Fourth Quar

Net sales of $200.3 million, an increase of 64% on a reported basis and an increase of 8% on a pro forma basis



Bone Growth Therapies growth of 15%, marking four consecutive quarters with...

Related Keywords

Canada , Lewisville , Texas , United States , Paris , France General , France , Toronto , Ontario , Italy , Ukraine , Munich , Bayern , Germany , Russia , United Kingdom , Brazil , Catherine Burzik , Massimo Calafiore , Exchange Commission , Orthofix Medical Inc , Nasdaq , Olive Branch , International Spinal Implants , Securities Exchange , Orthofix Medical , Months Ended December , Enabling Technologies , Spinal Implants , Ended December , Spinal Implant , Nasdaq Listing Rule , Chief Executive , Chief Executive Officer , Talent Development Committee , Nasdaq Marketplace Rule , Term Incentive Plan , Limitations Associated , Securities Exchange Act , Securities Act , Risk Factors , Annual Report , Quarterly Report , Markets ,